A Phase I, Open-label, Multicenter, Dose Escalation, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors

Trial Profile

A Phase I, Open-label, Multicenter, Dose Escalation, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2015

At a glance

  • Drugs MDX 1105 (Primary)
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms Anti-PDL-1
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 04 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
    • 27 Apr 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top